Originally published as JCO Early Release 10.1200/JCO.2004.05.009 on June 1 2004

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mandelblatt, J. S. Articles by Fahs, M. Search for Related Content PubMed PubMed Citation Articles by Mandelblatt, J. S. Articles by Fahs, M. Related Articles Related Editorial

Benefits and Costs of Interventions to Improve Breast Cancer Outcomes in African American Women

From the Department of Oncology, Georgetown University Medical Center, and Cancer Control Program, Lombardi Cancer Center, Washington, DC; Department of Family Medicine, Albert Einstein School of Medicine, Bronx; City University of New York, New York; Health Policy Research Center at the Robert J. Milano Graduate School of Management and Urban Policy at the New School for Social Research, New York, NY; and the Department of Health Studies and University of Chicago Cancer Research Center, University of Chicago, Chicago, IL

Address reprint requests to Jeanne Mandelblatt, MD, MPH, Lombardi Cancer Center, 2233 Wisconsin Ave, Suite 317, Washington, DC 20007; e-mail: mandelbj{at}georgetown.edu

PURPOSE: Historically, African American women have experienced higher breast cancer mortality than white women, despite lower incidence. Our objective was to evaluate whether costs of increasing rates of screening or application of intensive treatment will be off-set by survival benefits for African American women.

METHODS: We use a stochastic simulation model of the natural history of breast cancer to evaluate the incremental societal costs and benefits of status quo versus targeted biennial screening or treatment improvements among African Americans 40 years of age and older. Main outcome measures were number of mammograms, stage, all-cause mortality, and discounted costs per life year saved (LYS).

RESULTS: At the current screening rate of 76%, there is little incremental benefit associated with further increasing screening, and the costs are high: $124,053 and $124,217 per LYS for lay health worker and patient reminder interventions, respectively, compared with the status quo. Using reminders would cost $51,537 per LYS if targeted to virtually unscreened women or $78,130 per LYS if targeted to women with a two-fold increase in baseline risk. If all patients received the most intensive treatment recommended, costs increase but deaths decrease, for a cost of $52,678 per LYS. Investments of up to $6,000 per breast cancer patient could be used to enhance treatment and still yield cost-effectiveness ratios of less than $75,000 per LYS.

CONCLUSION: Except in pockets of unscreened or high-risk women, further investments in interventions to increase screening are unlikely to be an efficient use of resources. Ensuring that African American women receive intensive treatment seems to be the most cost-effective approach to decreasing the disproportionate mortality experienced by this population.

Supported by grants K05 CA96940 (J.S.M.) and RO1 CA72908 (J.S.M., K.R.Y., C.B.S., P.M., and M.F.) and cooperative agreement No. UO1-CA88293A from the National Cancer Institute (J.S.M., K.R.Y.,W.L., C.B.S., J.C., Y.C., and J.D.), Bethesda, MD.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

Related Editorial

• An Ounce of Prevention or a Pound of Cure? Investing to Improve Breast Cancer Outcomes for African American Women
  Hannah M. Linden, Scott Ramsey, and Nancy Anderson
  JCO 2004 22: 2517-2518 [Full Text]

This article has been cited by other articles:

				J. S. Mandelblatt, J. Cullen, W. F. Lawrence, A. L. Stanton, B. Yi, L. Kwan, and P. A. Ganz Economic Evaluation Alongside a Clinical Trial of Psycho-Educational Interventions to Improve Adjustment to Survivorship Among Patients With Breast Cancer J. Clin. Oncol., April 1, 2008; 26(10): 1684 - 1690. [Abstract] [Full Text] [PDF]

				N. K. Stout, M. A. Rosenberg, A. Trentham-Dietz, M. A. Smith, S. M. Robinson, and D. G. Fryback Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst, June 7, 2006; 98(11): 774 - 782. [Abstract] [Full Text] [PDF]

				D. J. Blackman and C. M. Masi Racial and Ethnic Disparities in Breast Cancer Mortality: Are We Doing Enough to Address the Root Causes? J. Clin. Oncol., May 10, 2006; 24(14): 2170 - 2178. [Abstract] [Full Text] [PDF]

				T. S. Field, D. S. M. Buist, C. Doubeni, S. Enger, H. Fouayzi, G. Hart, E. J. Korner, L. Lamerato, D. J. Bachman, J. Ellis, et al. Disparities and Survival Among Breast Cancer Patients J Natl Cancer Inst Monographs, November 1, 2005; 2005(35): 88 - 95. [Abstract] [Full Text] [PDF]

				S. J. DeNardo, C. M. Richman, H. Albrecht, P. A. Burke, A. Natarajan, A. Yuan, J. P. Gregg, R.T. O'Donnell, and G. L. DeNardo Enhancement of the Therapeutic Index: From Nonmyeloablative and Myeloablative toward Pretargeted Radioimmunotherapy for Metastatic Prostate Cancer Clin. Cancer Res., October 1, 2005; 11(19): 7187s - 7194s. [Abstract] [Full Text] [PDF]

				D. Hershman, R. McBride, J. S. Jacobson, L. Lamerato, K. Roberts, V. R. Grann, and A. I. Neugut Racial Disparities in Treatment and Survival Among Women With Early-Stage Breast Cancer J. Clin. Oncol., September 20, 2005; 23(27): 6639 - 6646. [Abstract] [Full Text] [PDF]

				H. M. Linden, S. Ramsey, and N. Anderson An Ounce of Prevention or a Pound of Cure? Investing to Improve Breast Cancer Outcomes for African American Women J. Clin. Oncol., July 1, 2004; 22(13): 2517 - 2518. [Full Text] [PDF]